People · Operator
Named in public records as an officer, director or promoter · active 2017–2024 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alamab Therapeutics Inc. | — | Biotechnology | Series A | $11.8M | $426.6M | 2017 |
| Neurock Pharmaceuticals Inc. | — | Pharmaceuticals | Series A | $10.0M | $59.9M | 2024 |
| Conjupro Biotherapeutics Inc. | — | Other | Series A | $9.3M | $54.5M | 2023 |
Qingxi Wang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Qingxi Wang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Haixing Wang | 2 | 2 |
| Lei Cai | 1 | 1 |
| JUMIN X. SUN | 1 | 1 |
| JEAN X. JIANG | 1 | 1 |
| YANFENG ZHANG | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.